Micropointbio
1 known investors
Shenzhen-based developer of MEMS and microfluidic lab-on-a-chip point-of-care diagnostic analyzers and test kits.
Also known as MBI · Micropoint Bio · MicroPoint Bioscience, Inc. · Micropoint Biotechnologies Co., Ltd.
Investors · 1
Company profile
researched Aug 2026Micropoint Biotechnologies Co., Ltd. (also referred to as MBI) develops, manufactures and sells lab-on-a-chip products built on MEMS (micro-electro-mechanical systems) and microfluidic technologies. Its portfolio targets rapid point-of-care diagnostics and self-testing, supplying medical professionals and patients with instruments and consumable test chips. Product lines include the mLabs platform, which uses microfluidic immunofluorescence for sensitive point-of-care immunoassay testing (products named mLabs ImmunoMeter and mLabs Smart), and the qLabs analyzer family, which applies electrochemistry to coagulation testing including PT, APTT, TT and FIB for clinical and veterinary use. The company has also offered a rapid COVID-19 test producing qualitative results in five minutes with a 10-test-per-run format, positioned for use at customs points, airports and isolation sites.
A related US entity, MicroPoint Bioscience, Inc., is described as a private company in Santa Clara, California, that provides rapid, accurate and low-cost point-of-care diagnostic products, with an mLabs platform based on patented semiconductor and microfluidic technologies integrated with immunoassay systems. Third-party company directories characterize the business as a small medical equipment manufacturer (NAICS 3391) offering customized, cost-effective lab-on-chip products for life science and health customers.
Business model
The company designs, manufactures and commercializes diagnostic analyzers and associated microfluidic test chips/consumables, and also offers customized lab-on-chip products and solutions for clients in life science and health-related fields.
Revenue derives from sales of point-of-care diagnostic instruments, test cartridges and customized microfluidic products, distributed through partner channels. Third-party estimates place annual revenue in the $1M-$10M range.
Traction
The company reports having developed more than 100 distribution partners worldwide. It exhibits at international trade events, including MEDICA in Germany (2023 and 2025), Africa Health 2023 in Johannesburg and Medlab Asia 2023 in Bangkok.
Latest developments
The company has publicized participation in MEDICA 2025 in Germany, alongside earlier appearances at MEDICA 2023, Africa Health 2023 and Medlab Asia 2023.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positioned as a small-to-mid-sized medical equipment manufacturer in microfluidic point-of-care diagnostics; directory listings name large diagnostics companies such as Thermo Fisher Scientific, Roche, Danaher, Abbott and Siemens Healthineers as comparable players.
Technology
Core technology combines MEMS fabrication and microfluidics in lab-on-a-chip formats. The mLabs platform uses microfluidic immunofluorescence, described elsewhere as based on patented semiconductor and microfluidic technologies integrated with immunoassay systems; the qLabs line uses electrochemical detection for coagulation parameters (PT, APTT, TT, FIB).
Go-to-market
Medical professionals, hospitals and clinical laboratories, veterinary users, patients performing self-tests, and life science research organizations seeking microfluidic and lab-on-chip capabilities; COVID-19 screening applications were aimed at customs, airports and isolation sites.
Geography
Headquartered in Shenzhen, China, with offices at 3-4F, Building 1, Runheng Electronics Factory, Liuxian 2 Road, Bao'an District, Shenzhen. A related US entity, MicroPoint Bioscience, Inc., is listed at 3333 Octavius Drive, Suite 110, Santa Clara, California. A third-party directory reports staff across Asia, North America and Europe, and the company reports 100+ distribution partners worldwide.
History
Micropoint Biotechnologies Co., Ltd. was established in 2007 and is headquartered in Shenzhen, China. The affiliated US entity MicroPoint Bioscience, Inc. is listed with a founding year of 2006 in Santa Clara, California. Product development has spanned electrochemical coagulation testing (qLabs), microfluidic immunofluorescence testing (mLabs) and rapid COVID-19 testing.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 4
launches, deals, and filingsCompany announced participation in the Africa Health 2023 trade event in Johannesburg.
Company announced participation in Medlab Asia 2023 in Bangkok.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 7
primary sources listed
- Contact | micropointbiomicropointbio.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Micropointbio do?
- Shenzhen-based developer of MEMS and microfluidic lab-on-a-chip point-of-care diagnostic analyzers and test kits.
- Who are Micropointbio's investors?
- Micropointbio's investors include Atinum Investment Co. Ltd..